Rituximab treatment of blistering disease

JRCT ID: jRCTs031180220

Registered date:15/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid
• Date of first enrollment: 01/05/2014
• Target sample size: 10
• Study type: Interventional
• Intervention(s): Infusion of rituximab (1000mg) intravenously. Approximately two weeks after the first dose, a second dose of rituximab is administered in a similar manner.

Outcome(s)

• Primary Outcome: Reduction of immunosuppressive agent and steroid dose.
• Secondary Outcome: Improvement of clinical symptoms, reduction of antibody titer.

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: < 80age old
• Gender: Both
• Include criteria: Patients who were diagnosed with pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid, with sufficient explanation and obtained research consent as sentences.
• Exclude criteria: Patients diagnosed as inappropriate by the judgment of the doctor.

Related Information

• Primary Sponsor: Kanaoka Miwa
• Secondary Sponsor: Michiko Aihara